Your session is about to expire
← Back to Search
Chemotherapy
Combination Chemotherapy for Non-Hodgkin's Lymphoma
Phase 1
Waitlist Available
Research Sponsored by Theradex
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Must have received 1 to 3 prior chemotherapy treatment regimens (may include doxorubicin up to a cumulative dose of no greater than 450 mg/m^2)
Cardiovascular: LVEF at least 50% by MUGA, No clinically significant cardiovascular abnormalities, No New York Heart Association class II-IV heart disease, No myocardial infarction within the past 6 months, No severe arrhythmia, No uncontrolled hypertension
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Study Summary
This trial is studying how well combination chemotherapy works in treating patients with aggressive non-Hodgkin's lymphoma that has returned or does not respond to treatment.
Who is the study for?
This trial is for people with aggressive non-Hodgkin's lymphoma that has come back or didn't respond to treatment. They should have tried 1-3 prior chemo treatments but not more, and can't have had too much doxorubicin before (no more than 450 mg/m^2). It's not for those with Burkitt's, lymphoblastic, or mantle cell lymphoma.Check my eligibility
What is being tested?
The study tests a combination of chemotherapy drugs on patients with relapsed or refractory aggressive non-Hodgkin's lymphoma. The goal is to find out how the body reacts to this mix of medications and if it can kill more cancer cells effectively.See study design
What are the potential side effects?
Chemotherapy can cause side effects like nausea, vomiting, hair loss, fatigue, increased risk of infection due to low blood cell counts, and potential damage to organs over time.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have had 1 to 3 chemotherapy treatments, possibly including doxorubicin but not exceeding a certain dose.
Select...
My heart is healthy with no recent heart attacks, severe irregular heartbeats, or uncontrolled high blood pressure.
Select...
My lymphoma is aggressive and has come back or didn't respond to treatment.
Select...
I am fully active or able to carry out light work.
Select...
My creatinine level is 1.5 mg/dL or lower.
Select...
I am between 18 and 64 years old.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Find a Location
Who is running the clinical trial?
TheradexLead Sponsor
33 Previous Clinical Trials
1,562 Total Patients Enrolled
3 Trials studying Lymphoma
80 Patients Enrolled for Lymphoma
Luis Fayad, MDStudy ChairM.D. Anderson Cancer Center
1 Previous Clinical Trials
60 Total Patients Enrolled
1 Trials studying Lymphoma
60 Patients Enrolled for Lymphoma
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have received less than 600 mg/m^2 of cisplatin in total.My cancer is not Burkitt's, lymphoblastic, or mantle cell lymphoma.I have had 1 to 3 chemotherapy treatments, possibly including doxorubicin but not exceeding a certain dose.My heart is healthy with no recent heart attacks, severe irregular heartbeats, or uncontrolled high blood pressure.My lymphoma is aggressive and has come back or didn't respond to treatment.I am fully active or able to carry out light work.My liver function tests are within acceptable limits and I don't have hepatitis B or C.My creatinine level is 1.5 mg/dL or lower.I am between 18 and 64 years old.
Research Study Groups:
This trial has the following groups:Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Does this research initiative admit participants who are senior citizens?
"This medical research is only open to participants who are of legal age and under 64."
Answered by AI
Has this remedy received endorsement from the FDA?
"Our team at Power have deducted that, due to the lack of data concerning efficacy and safety in phase 1 trials, this treatment was assigned a score of 1."
Answered by AI
Are there still vacancies available for participation in this research endeavor?
"According to clinicaltrials.gov, this trial is no longer actively enlisting participants. Initially posted on February 1st 2002 and last edited on July 4th 2009, it has since lost its recruitment status; however there are an abundance of alternative trials searching for volunteers currently."
Answered by AI
To what extent is this study being implemented across medical centers?
"This clinical trial is actively enrolling patients in 7 cities, including Cleveland, Memphis and Baltimore. To reduce the strain of travel when participating it is recommended to select the site closest to you."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger